uBriGene At Advanced Therapies Week 2026 | CGT Innovation

uBriGene Biosciences, a cell and gene therapy–focused CRDMO, will participate in Advanced Therapies Week 2026 (ATW 2026), taking place February 9–12, 2026, at the San Diego Convention Center. The annual event brings together global leaders in cell and gene therapy, advanced therapy manufacturing, and regulatory science to accelerate innovation and collaboration.

uBriGene provides end-to-end ATMP services, supporting programs from early-stage research and IND-enabling development through GMP manufacturing, quality control, and regulatory-ready testing. Leveraging robust, productivity-optimized CDMO platforms, uBriGene specializes in GMP plasmid manufacturing, RNA-LNP formulation, sgRNA production, viral vector development and GMP manufacturing, and cell therapy products.

At the conference, uBriGene will also feature LVV Turbo™, its next-generation GMP lentiviral vector manufacturing platform designed to increase productivity, improve recovery, and reduce cost of goods. 

uBriGene looks forward to connecting with partners and innovators in San Diego to explore collaboration opportunities and advance the next generation of cell and gene therapies.

Contact us to schedule a partnering meeting at Advanced Therapies Week 2026.